BeOne Medicines Reports Positive Phase 3 Survival Data for Ziihera Regimens
MT Newswires Live
3 hours ago
BeOne Medicines (ONC) said Monday that Ziihera plus chemotherapy showed statistically significant and clinically meaningful overall survival benefit in a phase 3 trial for HER2-positive gastroesophageal adenocarcinoma.
The trial met the remaining primary endpoint, with the combination regimen improving overall survival compared with trastuzumab plus chemotherapy, the company said.
The analysis also showed longer-term results for Ziihera with Tevimbra and chemotherapy, including an improved overall survival hazard ratio and durable outcomes, and a manageable safety profile, it said.
Shares of BeOne Medicines were 1.8% lower in Monday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.